MediSetter Interview:Â Insight on Opportunities in Asia's Healthcare Industry
Introduction to MedisetterI had the pleasure of interviewing Anirban Lahiri of Medisetter to discuss some of the opportunities present in Asia's...
4.2k Views
Profit from India's Rapidly Growing Biotechnology Industry
Now is a strategic time to focus on the upside potential of biotechnology companies in India, as India’s biotechnology industry is projected to...
5.1k Views
India's Budgets: 2006-2015. Key Charts, and Key questions
In continuation of my work of detailed work on India Budget for last ten years, this piece through simple charts puts in perspective: Â 2014 Actual...
557 Views
Shilpa Medicare: Strong FY25, FDF and Biologics, Focus on Asset Monetisation
​Shilpa's strong operational performance and focus on biologics signal a shift towards steady earnings and less reliance on one-off fees.
604 Views
Anthem Biosciences Pre-IPO - The Negatives- Margins Aren't There Yet
Anthem Biosciences is looking to raise up to US$400m in its upcoming India IPO. In this note, we talk about the not-so-positive aspects of the deal.
481 Views